Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 1, 2006, Pages 120-124

  Wasan, Kishor M ^a   Wong, Joyce C ^a   Corr, Traci ^b   Pritchard, Sheila ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Amphotericin B nephrotoxicity; Lipoprotein; Pediatric oncology

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; POTASSIUM; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CHILD; CHILDHOOD CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIET SUPPLEMENTATION; FEMALE; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MEDICAL RECORD; MYCOSIS; NEPHROTOXICITY; PRECIPITATION; PREDICTION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; AMPHOTERICIN B; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; CREATININE; FEMALE; HUMANS; INFANT; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MYCOSES; NEOPLASMS; PROGNOSIS; TRIGLYCERIDES;

EID: 28244484386     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0011-x     Document Type: Article

References (20)

1. Rothon DA, Mathias RG, Schechter MT (1994) Prevalence of HIV infection in provincial prisons in British Columbia. Can Med Assoc J 151:781-787
2. Meyer RD (1992) Current role of therapy with amphotericin B. Clin Infect Dis 14:S154-S168
3. Dunagan WC, Powderly WG (1989) Antimicrobials and Infectious Diseases. In: Dunagan WC, Ridner ML (eds) Manual of medical therapeutics. Little, Brown and Company, Boston, pp 251-252
4. Clements JS, Peacock JE (1990) Amphotericin B revisited: reassessment of toxicity. Am J Med 88:22N-27N
5. Llanos A, Cieza J, Bernardo J, Echevarria J, Biaggioni I, Sabra R, Branch RA (1991) Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 40:302-308
6. Koren G, Lau A, Klein J, Golas C, Bologa-Campeanu M, Soldin S, MacLeod SM, Prober C (1988) Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr 113:559-563
7. Hoeprich PD (1992) Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin Infect Dis 14:S114-S119
8. Nicholl T, Phillips P, Jewesson PJ (1994) Amphotericin B use in a major acute care hospital. Clin Ther 16:28-40
9. Anderson RJ, Schrier RW (1991) Acute renal failure. In: Wilson JD, Braunwald E, Isselbacher KJ et al (eds) Principles of internal medicine, 12th edn. McGraw Hill, New York, pp 1144-1150
10. Wasan KM, Kennedy AL, Cassidy SM et al (1998) The pharmacokinetics, serum lipoprotein and tissue distribution and renal toxicity of amphotericin B (AmpB) and amphotericin B lipid complex (ABLC) in a hypercholesterolemic rabbit model: single dose studies. Antimicrob Agents Chemother 42:3146-3152
11. Wasan KM, Conklin JS (1997) Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin Infect Dis 24:78-80
12. Wasan KM, Brazeau GA, Keyhani A et al (1993) Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother 37:246-250
13. Wasan KM, Morton RE, Rosenblum MG et al (1994) Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci 83:1006-1010
14. Wasan KM, Rosenblum MG, Cheung L et al (1994) Influence of lipoprotein-associated amphotericin B on its renal cytotoxicity and antifungal activity. Antimicrob Agents Chemother 38:223-228
15. Wasan KM, Cassidy SM (1998) Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J Pharm Sci 87:411-424
16. Ramaswamy M, Peteherych KD, Kennedy AL, Wasan KM (2001) Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob Agents Chemother 45:1184-1191
17. Luber AD, Maa L, Lam M et al (1999) Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 43:267-271
18. Fisher MA, Talbot GH, Maislin G et al (1989) Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 87:547-552
19. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686-693
20. Miller RP, Bates JH (1969) Amphotericin B toxicity: a follow-up report of 53 patients. Ann Intern Med 71:1089-1095